Abstract: The microfluidic chip can comprise at least one multichamber flow assembly that can comprise a plurality of microchannels. The plurality of microchannels can comprise a first microchannel that includes: a first inlet; a first outlet; and a first chamber fluidly connected to the first inlet and the first outlet. The plurality of microchannels can comprise a second microchannel that includes: a second inlet; a second outlet; and a second chamber fluidly connected to the second inlet and the second outlet. The multichamber flow assembly can comprise a porous biocompatible membrane oriented along a longitudinal interface between the first microchannel and the second microchannel, wherein the porous biocompatible membrane is permeable for movement of biomolecules from the first chamber to the second chamber through the porous biocompatible membrane.

Abstract: Disclosed are system and method that automate measurement of end users' quality-of-experience (QoE) when perceiving the video being streamed to the users' viewing devices. The overall user QoE is measured and computed by combining the instantaneous presentation quality, the playback smoothness quality, and the interactions between them. Prediction accuracy is thus significantly improved. The instantaneous and end-of-process QoE measures created by the system and method described are suitable for the monitoring and optimization of media streaming systems and services.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20—(Z)b—(Y)c—(R21)a—(X)d—R22—R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(?O), —S(?O)(?O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(?O)—, —S(?O)(?O)—, or —N(H)C(?O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

Abstract: Disclosed are system and method that auto-mate measurement of end users' quality-of-experience (QoE) when perceiving the video being streamed to the users' viewing devices. The overall user QoE is measured and computed by combining the instantaneous presentation quality, the playback smoothness quality, and the interactions between them. Prediction accuracy is thus significantly improved. The instantaneous and end-of-process QoE measures created by the system and method described are suitable for the monitoring and optimization of media streaming systems and services.

Abstract: An ultrasound-assisting quenching process includes: S1) connect the workpiece with the ultrasonic unit tightly; S2) heat the workpiece to the quenching temperature and then hold for a period of time; S3) start the ultrasonic unit, then the ultrasound energy can be injected into the workpiece directly; and S4) put the workpiece into the coolant quickly to make the workpiece to be quenched. The device for this process mainly includes the ultrasonic unit and a heating unit. This invention inputs the ultrasound energy into the workpiece during the quenching process. Under the action of the ultrasound, the grain size of the workpiece after quenching process will be much smaller compared with the conventional quenching process. Therefore, the ultrasound-assisting quenching process can improve the strength and plasticity of the material, and extend the life of the workpiece.

Abstract: A method, a deviceand electronic equipment for switching a name of a desktop icon folder are disclosed. The method includes: detecting a preset event (101); when the preset event is detected, control starting of a folder name switching process (102), which includes: firstly determining a system language used by current equipment (103); searching for a folder name corresponding to a language category of the system language from data of desktop icon folder names previously input by a user (104); when the folder name is found, switching a name of a desktop icon folder to the folder name corresponding to the language category of the system language (105).

Abstract: A titanium oxide-based supercapacitor electrode material and a method of manufacturing same. A reactive substance of the titanium oxide-based supercapacitor electrode material is a conductive titanium oxide. The conductive titanium oxide is a sub-stoichiometric titanium oxide, reduced titanium dioxide, or doped reduced titanium dioxide obtained by further doping an element in reduced titanium dioxide. The titanium oxide-based supercapacitor electrode material has a carrier concentration greater than 1018 cm?3, and the titanium oxide-based supercapacitor electrode material has a specific capacitance 20 F/g to 1,740 F/g at a charge/discharge current of 1 A/g.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20-(Z)b-(Y)c—(R21)a—(X)d—R22—R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(?O), —S(?O)(?O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, cycloalkenediyl, substituted cycloalkenediyl, alkatrienyl, substituted alkatrienyl; X is —C(?O)—, —S(?O)(?O)—, or —N(H)C(?O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno

Abstract: There is disclosed a method and system for objective video quality assessment. The objective video quality assessment approach automatically predicts human visual quality assessment behaviors in evaluating videos that contain artifacts generated during video acquisition, storage, reproduction, compression, transmission, processing, and/or display. The present method and system computes a five-dimensional quality map of a video being assessed, where the map indicates the local quality variations of the video in a five-dimensional space, which includes two spatial dimensions, one scale dimension, one time dimension, and one distortion type dimension. The present method and system may use one or a combination of device and viewing condition parameters in the generation of the quality map, and in the combination of the quality map into a scalar or vector-values measure that indicates quality aspects of the test videos.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20—(Z)b—(Y)c—(R21)a—(X)d—R22—R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(?O), —S(?O)(?O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(?O)—, —S(?O)(?O)—, or —N(H)C(?O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

Abstract: The present invention is a system and method for video coding. The video coding system may involve a structural similarity-based divisive normalization approach, wherein the frame prediction residual of the current frame may be transformed to form a set of coefficients and a divisive normalization mechanism may be utilized to normalize each coefficient. The normalization factor may be designed to reflect or approximate the normalization factor in a structural similarity definition. The Lagrange parameter for RDO for divisive normalization coefficients may be determined by both the quantization step and a prior distribution function of the coefficients. The present invention may generally be utilized to improve the perceptual quality of decoded video without increasing data rate, or to reduce the data rate of compressed video stream without sacrificing the perceived quality of decoded video. The present invention has shown to significantly improve the coding efficiency of MPEG4/H.

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: ?wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: Methods of making carbon nanostructures are disclosed with including examples having heat treatment of a mixture having a fibrous organic reagent and a catalyst in the presence of a reducing agent for a time sufficient to produce a quantity of carbon nanostructures which may be nanotubes or other related structures. The reducing agent may be hydrogen, nitrogen or ammonia.

Abstract: The present invention is a system or method that facilitates smart decision makings at the client side for adaptive video streaming over a video delivery network by making use of perceptual video quality-of-experience predictions performed during the video preparation stage, at the video hosting or cache server side, or inside the video delivery network, and then transmitted to the client. Compared with prior art approaches of adaptive bitrate video streaming, the present invention can result in one or more of the following benefits: 1) save the overall bandwidth for the delivery of the video content without scarifying the client users' quality-of-experience; 2) create better overall visual quality-of-experience of the client users; 3) create smoother visual quality-of-experience of the client users; and 4) reduce the probability of rebuffering or stalling events at the client user side.

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: There is disclosed a system and method for video coding, and more particularly to video coding that uses structural similarity (SSIM) based rate-distortion optimization methods to improve the perceptual quality of decoded video without increasing data rate, or to reduce the data rate of compressed video stream without sacrificing perceived quality of the decoded video. In an embodiment, the video coding system and method may be a SSIM-based rate-distortion optimization approach that involves minimizing a joint cost function defined as the sum of a data rate term and a distortion functions. The distortion function may be defined to be monotonically increasing with the decrease of SSIM and a Lagrange parameter may be utilized to control the trade-off between rate and distortion. The optimal Lagrange parameter may be found by utilizing the ratio between a reduced-reference SSIM model with respect to quantization step, and a data rate model with respect to quantization step.

Abstract: Methods of making carbon nanostructures are disclosed with including examples having heat treatment of a mixture having a fibrous organic reagent and a catalyst in the presence of a reducing agent for a time sufficient to produce a quantity of carbon nanostructures which may be nanotubes or other related structures. The reducing agent may be hydrogen, nitrogen or ammonia.